Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RB activation defect in tumor cell lines.

Cristina Broceño1, Scott Wilkie, Sibylle Mittnacht

  • 1Centre for Molecular and Cell Biology, Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, United Kingdom.

Proceedings of the National Academy of Sciences of the United States of America
|October 16, 2002
PubMed
Summary

Certain tumor cells fail to activate the retinoblastoma (RB) protein in response to DNA damage or cell cycle changes. This defect leads to genomic instability and accelerated cell death, suggesting new therapeutic targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microenvironment matters: insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy.

Cancer metastasis reviews·2025
Same author

Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors.

Cancer research·2024
Same author

Brain endothelial cells promote breast cancer cell extravasation to the brain via EGFR-DOCK4-RAC1 signalling.

Communications biology·2024
Same author

Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.

JCO precision oncology·2022
Same author

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma.

Nature communications·2021
Same author

Simultaneous expression of MMB-FOXM1 complex components enables efficient bypass of senescence.

Scientific reports·2021

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Genetics

Background:

  • The retinoblastoma (RB) protein is a key regulator of the cell cycle, typically activated by dephosphorylation upon exiting mitosis or in response to DNA damage.
  • Dysregulation of RB protein inactivation is common in tumors, but its activation pathway's integrity in cancer is less understood.

Purpose of the Study:

  • To investigate the coordinated regulation of RB protein activation in tumor-derived cell lines.
  • To determine if defects in RB activation contribute to cellular phenotypes associated with genomic instability and DNA damage sensitivity.

Main Methods:

  • Analysis of RB protein dephosphorylation during cell cycle progression (G1 phase).
  • Assessment of RB activation following DNA damage during S phase.

Related Experiment Videos

  • Evaluation of cellular responses, including apoptosis and DNA re-replication, after spindle-checkpoint activation.

    • Main Results:

    • A subset of tumor-derived cell lines exhibited impaired RB dephosphorylation during G1 and failed to activate RB after DNA damage.
    • These cells displayed phenotypes characteristic of RB-deficient cells, such as accelerated apoptosis post-DNA damage.
    • Spindle-checkpoint activation in these cells led to DNA re-replication, indicating compromised cell cycle control.

    Conclusions:

    • The study identifies a novel defect in RB protein activation, distinct from previously known inactivation defects, in a subset of tumor cells.
    • Compromised RB activation is linked to increased DNA damage sensitivity and genomic instability.
    • These findings highlight potential new therapeutic strategies targeting RB activation pathways in cancer.